Annual Total Long Term Liabilities
$61.51 M
+$58.61 M+2018.95%
December 31, 2022
Summary
- As of February 8, 2025, EGRX annual total long term liabilities is $61.51 million, with the most recent change of +$58.61 million (+2018.95%) on December 31, 2022.
- During the last 3 years, EGRX annual total long term liabilities has risen by +$24.96 million (+68.27%).
- EGRX annual total long term liabilities is now at all-time high.
Performance
EGRX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$66.15 M
-$7.37 M-10.02%
June 30, 2023
Summary
- As of February 8, 2025, EGRX quarterly total long term liabilities is $66.15 million, with the most recent change of -$7.37 million (-10.02%) on June 30, 2023.
- Over the past year, EGRX quarterly long term liabilities has increased by +$31.34 million (+90.04%).
- EGRX quarterly long term liabilities is now -10.02% below its all-time high of $73.52 million, reached on March 31, 2023.
Performance
EGRX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
EGRX Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2019.0% | +90.0% |
| 3 y3 years | +68.3% | +105.1% |
| 5 y5 years | +41.0% | +63.5% |
EGRX Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +2019.0% | -10.0% | +2481.0% |
| 5 y | 5-year | at high | +2019.0% | -10.0% | +2481.0% |
| alltime | all time | at high | -100.0% | -10.0% | -100.0% |
Eagle Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $66.15 M(-10.0%) |
| Mar 2023 | - | $73.52 M(+19.5%) |
| Dec 2022 | $61.51 M(+2018.9%) | $61.51 M(+87.3%) |
| Sep 2022 | - | $32.84 M(-5.7%) |
| Jun 2022 | - | $34.81 M(+1258.2%) |
| Mar 2022 | - | $2.56 M(-11.7%) |
| Dec 2021 | $2.90 M(-90.0%) | $2.90 M(-87.1%) |
| Sep 2021 | - | $22.54 M(-8.9%) |
| Jun 2021 | - | $24.73 M(-8.1%) |
| Mar 2021 | - | $26.92 M(-7.5%) |
| Dec 2020 | $29.09 M(-20.4%) | $29.09 M(-2.6%) |
| Sep 2020 | - | $29.86 M(-7.4%) |
| Jun 2020 | - | $32.26 M(-5.8%) |
| Mar 2020 | - | $34.23 M(-6.4%) |
| Dec 2019 | $36.56 M(-4.2%) | $36.56 M(-6.1%) |
| Sep 2019 | - | $38.91 M(+4.0%) |
| Jun 2019 | - | $37.40 M(-6.2%) |
| Mar 2019 | - | $39.87 M(+4.5%) |
| Dec 2018 | $38.16 M | $38.16 M(-2.9%) |
| Sep 2018 | - | $39.31 M(-2.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $40.47 M(-4.5%) |
| Mar 2018 | - | $42.36 M(-2.9%) |
| Dec 2017 | $43.61 M(+97.1%) | $43.61 M(-29.0%) |
| Sep 2017 | - | $61.42 M(+168.6%) |
| Jun 2017 | - | $22.86 M(+1.4%) |
| Mar 2017 | - | $22.55 M(+1.9%) |
| Dec 2016 | $22.13 M(>+9900.0%) | $22.13 M(+284.5%) |
| Sep 2016 | - | $5.75 M(+0.0%) |
| Jun 2016 | - | $5.75 M(+4.3%) |
| Mar 2016 | - | $5.52 M(>+9900.0%) |
| Dec 2015 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2015 | - | $0.00(0.0%) |
| Jun 2015 | - | $0.00(0.0%) |
| Mar 2015 | - | $0.00(0.0%) |
| Dec 2014 | - | $0.00(0.0%) |
| Sep 2014 | $0.00(-100.0%) | $0.00(0.0%) |
| Jun 2014 | - | $0.00(0.0%) |
| Mar 2014 | - | $0.00(0.0%) |
| Dec 2013 | - | $0.00(-100.0%) |
| Sep 2013 | $1.71 M(+160.8%) | $1.71 M |
| Sep 2012 | $654.50 K | - |
FAQ
- What is Eagle Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals annual total long term liabilities year-on-year change?
- What is Eagle Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Eagle Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of EGRX is $61.51 M
What is the all time high annual total long term liabilities for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual total long term liabilities is $61.51 M
What is Eagle Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, EGRX annual total long term liabilities has changed by +$58.61 M (+2018.95%)
What is Eagle Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of EGRX is $66.15 M
What is the all time high quarterly long term liabilities for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly total long term liabilities is $73.52 M
What is Eagle Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, EGRX quarterly total long term liabilities has changed by +$31.34 M (+90.04%)